Leslie Isenegger, Principal Strategist for Reputation & Risk Management Practice at inVentiv Health Communications, addresses the topic of orphan drug pricing in this article published in Pharmaceutical Executive.
Institute for Clinical and Economic Review (ICER) recently "released a whitepaper acknowledging that value assessments of orphan and ultra-orphan medicines are more challenging than for other types of treatments. This is partly due to distinctive clinical, regulatory, and payer contexts in which these treatments are developed or used, ICER conceded." Leslie talks about how manufacturers should respond to the framework revisions that ICER has proposed.
This content is repurposed from Pharmaceutical Executive.
